Effects of the soluble guanylyl cyclase activator, YC‐1, on vascular tone, cyclic GMP levels and phosphodiesterase activity

Publisher Website
Google Scholar
Abstract
The vasomotor and cyclic GMP‐elevating activity of YC‐1, a novel NO‐independent activator of soluble guanylyl cyclase (sGC), was studied in isolated rabbit aortic rings and compared to that of the NO donor compounds sodium nitroprusside (SNP) and NOC 18. Similarly to SNP and NOC 18, YC‐1 (0.3–300 μM) caused a concentration‐dependent, endothelium‐independent relaxation that was greatly reduced by the sGC inhibitor 1‐H‐[1,2,4]oxadiazole[4,3‐a]quinoxalin‐1‐one (ODQ 10 μM; 59% inhibition of dilation induced by 100 μM YC‐1) suggesting the activation of sGC as one mechanism of action. Preincubation with YC‐1 (3 and 30 μM) significantly increased the maximal dilator responses mediated by endogenous NO in aortic rings that was released upon exposure to acetylcholine, and enhanced the dilator response to the exogenous NO‐donors, SNP and NOC 18, by almost two orders of magnitude. Vasoactivity induced by SNP and YC‐1 displayed different kinetics as evidenced by a long‐lasting inhibition by YC‐1 (300 μM) on the phenylephrine (PE)‐induced contractile response, which was not fully reversible even after extensive washout (150 min) of YC‐1, and was accompanied by a long‐lasting elevation of intracellular cyclic GMP content. In contrast, SNP (30 μM) had no effect on the vasoconstrictor potency of PE, and increases in intravascular cyclic GMP levels were readily reversed after washout of this NO donor compound. Surprisingly, YC‐1 not only activated sGC, but also affected cyclic GMP metabolism, as it inhibited both cyclic GMP break down in aortic extracts and the activity of phosphodiesterase isoforms 1–5 in vitro. In conclusion, YC‐1 caused persistent elevation of intravascular cyclic GMP levels in vivo by activating sGC and inhibiting cyclic GMP break down. Thus, YC‐1 is a highly effective vasodilator compound with a prolonged duration of action, and mechanisms that are unprecedented for any previously known sGC activator. British Journal of Pharmacology (1999) 127, 195–203; doi:10.1038/sj.bjp.0702495